Various embodiments relate generally to in vitro diagnostic devices and methods for testing for various viruses and bacteria, such as, for example, Streptococcus.
Every year, millions of anxious parents bring their children into a clinic, urgent care facility or emergency room presenting symptoms of pharyngitis or Group A strep. This can be a time-consuming and expensive appointment—often consuming a half-day of work or school and ultimately costing the parents $150-250 in office visit charges. And for the parents that take this step of bringing their children to a medical facility for both a rapid-test diagnosis and a longer culture-based test, 80% are sent home with negative rapid-test results, with little more than instructions to provide their ailing children with rest, fluids, over-the-counter acetaminophen and a promise of follow-up if the a more thorough culture-based test comes back positive in the following days. For many, the culture-based test does come back positive a day or two later, and the parents and their children must return to the clinic to be examined in person and for medication to be prescribed. The prescription must then be filled and picked up, often at an off-site pharmacy—adding additional time-consuming and expensive steps to the diagnosis and treatment process.
In some implementations, an in vitro test device includes a plunger, a housing, one or more reagent pouches, a lateral flow test strip, and a locking member.
The plunger may have a plunger axis; a cylindrical plunger sidewall that is parallel to the plunger axis; a plunger base that is perpendicular to the plunger axis and open in the middle to enable communication with an interior of the plunger; a piercing member that is open in the middle to enable fluid communication with the interior and that has a smaller cross-sectional area than that bounded by the one or more plunger sidewalls; a test strip channel disposed in a sidewall in the one or more plunger sidewalls; a diaphragm member disposed in the plunger; and ridges disposed on an interior wall of the plunger.
The housing may have a housing axis; a cylindrical housing sidewall that is parallel to the housing axis; a housing base on a housing base end, which is perpendicular to the housing axis and closed in the middle, such that the housing base and the cylindrical housing sidewall forms a liquid-impermeable vessel; and an open end opposite the housing base that slidably receives the plunger.
The one or more reagent pouches may be disposed inside the housing, adjacent the housing base end, in a reagent region. The lateral flow test strip may be disposed in the test strip channel. The locking member may have a first configuration and a second configuration. In the first configuration, the locking member may prevent the piercing member from impinging into the reagent region. In the second configuration, the locking member may allow the plunger to be translated into the housing such that the piercing member impinges into the reagent region. The diaphragm member may be configured to prevent reagent from the one or more reagent pouches from leaking out of the interior when the reagent has been released from the one or more reagent pouches and when the in vitro test device is positioned vertically on its plunger base. The ridges may be configured to compress a sample collection portion of a test swab, as the test swab is passed into the interior.
In some implementations, an in vitro test device includes a plunger, a housing, one or more reagent pouches, a lateral flow test strip and a locking member.
The plunger may have a plunger axis; one or more plunger sidewalls that are parallel to the plunger axis; a plunger base that is perpendicular to the plunger axis and open in the middle to enable communication with an interior of the plunger; a piercing member that is open in the middle to enable fluid communication with the interior and that has a smaller cross-sectional area than that bounded by the one or more plunger sidewalls; and, a test strip channel disposed in a sidewall in the one or more plunger sidewalls.
The housing may have a housing axis; one or more housing sidewalls that are parallel to the housing axis; a housing base on a housing base end, which is perpendicular to the housing axis and closed in the middle, such that the housing base and the one or more housing sidewalls form a liquid-impermeable vessel; and an open end opposite the housing base that slidably receives the plunger.
The one or more reagent pouches may be disposed inside the housing, adjacent the housing base end, in a reagent region. The lateral flow test strip may be disposed in the test strip channel. The locking member may have a first configuration and a second configuration. In the first configuration, the locking member may prevent the piercing member from impinging into the reagent region. In the second configuration, the locking member may allow the plunger to be translated into the housing such that the piercing member impinges into the reagent region.
In some implementations, the one or more sidewalls comprise a single sidewall having a generally cylindrical form. In some implementations, the one or more sidewalls comprise four sidewalls having a generally square cross section.
The in vitro test device may further include a diaphragm member disposed in the plunger. The diaphragm member may be configured to prevent reagent that has been released from the one or more reagent pouches from leaking out of the interior when the in vitro test device is positioned vertically on its plunger base. The test strip channel may include an opening into the interior, such that when a test strip is disposed in the test strip channel, a portion of the test strip is adjacent the diaphragm member.
The plunger may further include ridges disposed on an interior wall of the plunger and spaced to compress a sample collection portion of a test swab, as the test swab is passed into the interior.
At least one of the plunger base and housing base may include a flat edge that prevents the in vitro test device from rolling when the in vitro test device is positioned horizontally relative to a surface and the flat edge is in contact with the surface.
In some implementations, each of the plunger base and the housing base include a flat edge, and the in vitro test device further includes a keying mechanism to align the plunger and housing in a fixed orientation relative to each other and to a plunger axis and a housing axis.
In some implementations, the in vitro test device further includes indicia on at least one of the plunger base or housing base. The indicia may provide a user with instructions regarding using the in vitro test device. The indicia may include indicia to guide manipulation of the plunger relative to the housing, or a test swab associated with the in vitro test device relative to the plunger. The indicia may include indicia to guide a user with respect to a time period during which the in vitro test device is to be positioned in a specific spatial orientation.
In some implementations, a method of identifying the presence of an analyte includes providing an in vitro test device and a test swab; obtaining a sample using the test swab; transitioning a locking member from a first configuration to a second configuration; advancing a plunger into a housing to pierce one or more reagent pouches in a reagent region to cause reagent therein to be released and mix; inserting the test swab with an obtained sample into the interior of the plunger; rotating the in vitro test device and disposing it on a plunger base; and determining whether the analyte is present.
The in vitro test device may include (a) a plunger having a plunger axis; one or more plunger sidewalls that are parallel to the plunger axis; a plunger base that is perpendicular to the plunger axis and open in the middle to enable communication with an interior of the plunger; a piercing member that is open in the middle to enable fluid communication with the interior and that has a smaller cross-sectional area than that bounded by the one or more plunger sidewalls; and, a test strip channel disposed in a sidewall in the one or more plunger sidewalls; (b) a housing having a housing axis; one or more housing sidewalls that are parallel to the housing axis; a housing base on a housing base end, which is perpendicular to the housing axis and closed in the middle, such that the housing base and the one or more housing sidewalls form a liquid-impermeable vessel; and an open end opposite the housing base that slidably receives the plunger; (c) one or more reagent pouches disposed inside the housing, adjacent the housing base end, in a reagent region; (d) a lateral flow test strip disposed in the test strip channel; (e) a locking member having a first configuration and a second configuration; wherein, in the first configuration, the locking member prevents the piercing member from impinging into the reagent region, and wherein, in the second configuration, the locking member allows the plunger to be translated into the housing such that the piercing member impinges into the reagent region.
The method may further include agitating at least one of the test swab or the in vitro test device. Rotating the in vitro test device may include rotating after an extraction incubation period. A mixing incubation period may separate the advancing and inserting steps. Determining may include determining based on observation of a results section of the lateral flow test strip. Determining may include determining after a testing incubation period.
At least one of the plunger base and the housing base may include a flat edge, and the method may further include rotating the in vitro test device such that its plunger axis and housing axis are parallel to a horizontal surface, and resting the flat edge on the horizontal surface.
Described herein are various implementations of in vitro test devices and kits that can be used in an at-home setting to determine the presence of certain analytes, such as, for example a carbohydrate antigen that is unique to Group A Streptococcus bacteria. Such bacteria can cause strep throat, impetigo, cellulitis and other skin and soft tissue infections. By detecting its presence, or confirming its absence, appropriate treatment may be coordinated—in some cases, from home, without an expensive, time-consuming, burdensome, risk-enhancing visit to a clinic. Analytes other than those associated with Group A Streptococcus may also be detected with the implementations described herein.
A user may employ the test swab 103 to take a biological sample (e.g., a pharyngeal sample), then employ the in vitro test device 100 in the manner described herein to determine—via a rapid, at-home test—whether the bacteria of interest is present, such that appropriate follow-up action can be taken (e.g., a prescription antibiotic secured).
As shown in
On one end of the plunger 106 is disposed a plunger base 115, which, in some implementations, is perpendicular to the plunger axis 109. The plunger base 115 is open in the middle (not visible in
Opposite the plunger base 115, on a piercing end 127 of the plunger 106, is disposed a piercing member 124. The piercing member 124 is, in some implementations, an angled or sharpened protrusion that has a smaller diameter (and smaller cross-sectional surface area) than a diameter (or cross-sectional surface area bounded by the sidewalls) of the plunger 106 itself.
Like the plunger base 115, the piercing member 124 is open in the middle to enable communication with the interior 121 of the plunger. In operation, the test swab 103 may be slid into and through the interior 121, through the open middle of the plunger base 115, through the middle of the plunger 106 and out the middle of the piercing member 124.
The test device 100 further includes a housing 148 having a housing axis 151. The housing 148 has a housing sidewall 154 that is parallel to the housing axis 151, and a housing base 157, on a base end 160 of the housing, which is perpendicular to the housing axis 151. The housing base 157 is closed in the middle, such that the housing base 157 and the sidewall 154 form a closed (e.g., liquid-impermeable) vessel 163.
On the housing 148, opposite the housing base end 160, is an open end 164, which is configured to slidably receive the plunger 106. That is, the plunger 106 and housing 148 are configured such that plunger 106 can slide inside the housing 148 with a relatively tight fit (in some implementations, a liquid-tight fit), yet loose enough to permit translation of the two components during operation of the device 100.
In some implementations, the housing base 157 may include a flattened edge 158 to enable the device 100 to lay flat on a horizontal surface without rolling. The plunger base 115 may also have a flattened surface 116. In some implementations, only one of the plunger base 115 or housing base 157 has a flattened edge (116 or 158, respectively); in other implementations, both plunger base 115 and housing base 157 have flatted edges 116 and 158, and the plunger 106 and housing 148 may be keyed in some manner to maintain like orientation of the two flattened edges 116 and 158.
As shown, the test device 100 further includes reagent pouch 185 and reagent pouch 186. In some implementations, the reagent pouches 185 and 186 are disposed inside the housing 148 adjacent the base end 160, in a reagent region 188. The reagent pouches 185 and 186 may be constructed with sidewalls that are configured to fit into the housing 148; in some implementations, a top and bottom surface (e.g., surfaces that are perpendicular to the housing axis 151) are constructed of a foil or other thin material that is easily ruptured, e.g., by translation of the piercing member 124 into the reagent region 188. The function of the reagent pouches is explained with reference to a lateral flow test strip 166, and with reference to a lateral flow test strip 366 in
The process of preparing a sample for application to the lateral flow test strip 366 are briefly described. A sample may be collected in various ways, depending on the type of sample and its origin. For example, a urine sample may be collected directly on the lateral flow test strip 366 (e.g., in the case of a pregnancy test); as another example, a sample, such as a pharyngeal saliva sample, may be collected on a swab (e.g., the swab 103) or other sample collection device. In cases in which a swab or other sample device is used to collect a sample, the sample may be extracted into a liquid media that can then be transferred to the lateral flow test strip.
In some implementations, the sample is extracted by an acid, such as nitrous acid. Such an acid may serve as an oxidizing agent that breaks down cell walls of an antigen-containing target bacteria (e.g., Streptococcus bacteria), to release the analyte of interest. Acids that are useful in such extraction processes may be very unstable; thus, it may be important to prepare the acids immediately prior to use.
One way these acids can be formed is with separate reagents that are mixed immediately prior to sample extraction. For example, in some implementations, two reagents are used—one containing a nitrite salt, such as a sodium nitrite solution, and one containing an acid, such as acetic acid. In such implementations, the combination of sodium nitrite and acetic acid produce nitrous acid. In other implementations, different reagents may be employed—such as, for example, phosphoric acid, citric acid, guanidinium thiocyanate, sodium hydroxide, etc.
In some implementations, dyes may be added, or the reagents may be selected, such that a color change occurs when the reagents are mixed. In such implementations, the color change can provide a user with confirmation that the reagents have been mixed and are ready to receive a sample for extraction and testing.
In some implementations, the separate pouches 185 and 186 (
The exemplary lateral flow test strip 366 includes a sample pad 391—the location at which sample liquid is applied. The sample pad 391 is absorbent and may, in some cases, include buffer salts and/or surfactants to assist a sample in flowing across the lateral flow test strip 366. Adjacent the sample pad is a conjugate release pad 392. In some implementations, the conjugate release pad 392 includes mobile detection particles that bind to target analytes. These detection particles may also be bound to colored or fluorescent particles—colloidal gold or latex microspheres in some implementations. Thus, in the conjugate release pad 392, conjugates are formed between target analytes and the detection particles.
The lateral flow test strip 366 includes a membrane that 393 that causes the liquid sample (including the extracted analyte and any conjugate formed between extracted analyte and detection particles) to flow from the sample pad 391, towards an absorbent pad 397. Between the sample pad 391 and the absorbent pad 397 lies a test line 394 (or, in some cases, more than one test line) and a control line 395.
The test line 394 may comprise immobilized antibodies or antigens that are configured to react with target analytes, causing the detection particles to be aggregated at the test line 394. After enough target detection particles aggregate at the test line 394, they may be visually apparent as a line having a contrasting color relative to the membrane 393. If target analytes are not present in the solution passing the test line 394, no reaction occurs, and the conjugate analyte/detection particles flow past the test line 394 without aggregating into a visual line.
The lateral flow test strip 366 further includes a control line 395 that confirms proper capillary flow of the test solution across the membrane 393. In some implementations, the control line 395 appears as a visual line as soon as test solution flows past—regardless of whether a target analyte is present or not. The appearance of this line may provide some confirmation that the lateral flow test strip 366 is properly functioning.
As shown, the sample pad 391, conjugate release pad 392, membrane 393 with test strip 394 and control strip 395, and the absorbent pad 397 are all supported by a backing card 396—typically a substrate (e.g., thick paper, cardboard, plastic, polymer, etc.) to support and configure relative to each other the components of the later flow test strip 366.
Returning to
As shown, the test device 100 also includes a diaphragm member 191 disposed in the plunger. As will be explained in more detail with reference to other figures, in some implementations, the diaphragm 191 member is configured to provide a liquid seal around a test swab 103, when said test swab 103 is inserted into and through the plunger 106.
In some implementations, as shown in
As depicted in
As depicted in
In some implementations, the mixing of the reagents contained in the reagent pouch 186 and the reagent pouch 185 causes a solution to be formed that is suitable for extracting a sample from the swab 103. For example, in some implementations, reagent pouch 186 contains sodium nitrite solution, reagent pouch 185 contains acetic acid, and when the two reagent pouches 186 and 185 are pierced and their contents are combined, nitrous acid is a formed—an acid that may be effective in extracting a sample from the swab 103.
As depicted in
In some implementations, the housing 148 and plunger 106 are agitated for a short period of time, prior to the swab 103 being inserted. In some implementations, a short “mixing incubation period” may also be provided prior to the swab being inserted 103 (e.g., to enable the multiple reagents to fully mix). The desire or need for agitation or incubation may depend on the specific reagents employed and the nature of a target sample.
As depicted in
As shown in one implementation, the swab 103 remains disposed in the test device 100 once it is rotated. In such implementations, the diaphragm 191 (shown in
As depicted in
In some implementations, the test device 100 is not rotated horizontally until after a “testing incubation period”—a period of time during which (with reference to
The method 500 further includes obtaining (504) a sample using the test swab. For example, a user may obtain a pharyngeal saliva sample from a patient using the test swab 103.
The method 500 further includes releasing (507) the locking mechanism. For example, with reference to
The method 500 further includes disposing (508) the device on its housing base (e.g., vertically oriented, on the housing base 157—for example, as shown in
The method 500 further includes advancing (510) the plunger into the housing. For example, with reference to
The method 500 further includes inserting (513) the test swab into the plunger. For example, with reference to
The method 500 further includes, in some implementations, agitating (516) the test device. This step could include, for example, “swirling” the test device 100 or test swab 103 in a circular motion to agitate the extraction fluid and increase its interaction with the test swab—to promote or expedite extraction of a sample contained on the test swab. The method 500 further includes waiting (517) for an “extraction incubation period” of time, to allow for sufficient sample to be extracted by and into the extraction solution, from the test swab.
The method 500 further includes rotating (519) the test device. For example, with reference to
The method 500 further includes waiting (520) for a “testing incubation period” of time. In some implementations, this period of time allows the extraction fluid to wick up the lateral flow test strip (e.g., the membrane 393), such that any target analyte in the extraction fluid will cause a test line 394 to appear; regardless of the presence of any target analyte, in some implementations, wicking of the extraction fluid past the control line 395 will cause a visible line to appear there.
The method 500 further includes determining (522) whether an analyte is present. In some implementations, this includes determining (522) whether a test line is present on the lateral flow test strip. For example, with reference to
In some implementations, steps in the method 500 may be reordered or omitted, or other steps may be added. For example, in some implementations, it may not be necessary to agitate (516) the test device. In some implementations, it may not be necessary to wait (511) for a mixing incubation period of time. In some implementations, the locking clip may be removed (507), the test device disposed (508) on its base, and the plunger advanced (510) prior to the sample being obtained (504); in this manner, the sample may be obtained while the user is waiting (511) for any necessary incubation period of time. In some implementations, the test swab may be removed from the test device prior to the test device being rotated (519). In such implementations, removal of the test swab facilitate a “squeezing” of the tip of the test swab by a diaphragm (e.g., the diaphragm 191 shown in
In some implementations, such as the one shown, the diaphragm member 191 has a protrusion 692 that interfaces with an opening 693 in the plunger body (see also
As shown in
On one end of the plunger 806 is disposed a plunger base 815, which, in some implementations, is perpendicular to the plunger axis 809. The plunger base 815 is open in the middle to allow communication with an interior 821 of the plunger 806. In some implementations, as shown, the plunger 806 is made up of two different portions—one portion including the primary sidewall 812, and one portion including the base 815; such implementations may be configured to retain a diaphragm member 891, which may be included and configured to provide a seal around a test swab 803, when said test swab 803 is inserted into and through the plunger 806. In other implementations, the plunger 806 may be a single unitary piece that includes both the primary sidewall 812 and the plunger base 815.
Opposite the plunger base 815, on a piercing end 827 of the plunger 806, is disposed a piercing member 824. The piercing member 824 is, in some implementations, an angled or sharpened protrusion (or multiple protrusions, as shown in one implementation) that has a smaller diameter (and smaller cross-sectional surface area) than a diameter (or cross-sectional surface area bounded by the sidewalls) of the plunger 806 itself.
Like the plunger base 815, the piercing member 824 is open in the middle to enable communication with the interior 821 of the plunger. In operation, the test swab 803 may be slid into and through the interior 821, through the open middle of the plunger base 815, through the middle of the plunger 806 and out the middle of the piercing member 824.
The test device 800 further includes a housing 848 having a housing axis 851. The housing 848 has a housing sidewall 854 that is parallel to the housing axis 851, and a housing base 857, on a base end 860 of the housing, which is perpendicular to the housing axis 851. The housing base 857 is closed in the middle, such that the housing base 857 and the sidewall 854 form a closed (e.g., liquid-impermeable) vessel 863.
On the housing 848, opposite the housing base end 860, is an open end 864, which is configured to slidably receive the plunger 806. That is, the plunger 806 and housing 848 are configured such that plunger 806 can slide inside the housing 848 with a relatively tight fit (in some implementations, a liquid-tight fit), yet loose enough to permit translation of the two components during operation of the device 800.
In some implementations, the housing base 857 may include a flattened edge 858 to enable the device 800 to lay flat on a horizontal surface without rolling. The plunger base 815 may also have a flattened surface 816. In some implementations, only one of the plunger base 815 or housing base 857 has a flattened edge (816 or 858, respectively); in other implementations, both plunger base 815 and housing base 857 have flatted edges 816 and 858, and the plunger 806 and housing 848 may be keyed in some manner to maintain like orientation of the two flattened edges 816 and 858 (e.g., by a raised nub 881 and corresponding open slot 882, as shown in one implementation).
As shown, the test device 800 further includes reagent pouch 885 and reagent pouch 886. In some implementations, the reagent pouches 885 and 886 are disposed inside the housing 848 adjacent the base end 860, in a reagent region 888. The reagent pouches 885 and 886 may be constructed with sidewalls that are configured to fit into the housing 848; in some implementations, a top and bottom surface (e.g., surfaces that are perpendicular to the housing axis 151) are constructed of a foil, plastic, polymer, or other thin membrane that is easily ruptured, e.g., by translation of the piercing member 824 into the reagent region 888, but that seals and retains reagents until the piercing member 824 releases them.
In some implementations, as shown in
In some implementations, as shown, indicia 879 (e.g., lock symbol and/or a directional arrow) may be formed on the locking member 875, to guide users in the operation of the device 800. In some implementations, the locking member 875 may be colored differently, relative to the plunger 806 and/or plunger base 815, to make the locking member 875 stand out visually (e.g., the locking member may be colored red or green, relative to a gray or white color of the plunger 806).
Other indicia may be employed on the device 800, as shown in
With reference to
In some implementations, the diaphragm 891 may also provide a seal that substantially prevents reagent (or much reagent) from leaking out of the interior space 821 (whether or not the test swab 803 is in place), when the test device is rotated such that its plunger base 815 is on the bottom.
Turning to
The action of depressing the plunger 806 into the housing 848 is depicted in a second step in
In a third step depicted in
In a fourth step depicted in
In a fifth step depicted in
In a sixth step (first frame) depicted in
In a seventh step depicted in
As depicted in an eighth step in
As depicted in a ninth step in
As depicted in a tenth step in
As depicted in a eleventh step in
In some implementations, a period of time is required for the reagent/sample mixture to be drawn into the test strip. This waiting period (e.g., one minute, two minutes, five minutes, ten minutes, etc.—as specified in instructions associated with the device) is depicted in a twelfth step in
While various implementations have been described with reference to exemplary aspects, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the contemplated scope. For example, a cylindrical housing is described, but housing could take another shape, such as one with a square cross-section. Two reagents are described, but in some implementations, there may be a single reagent; in other implementations, there may be three or more reagents. A lateral flow test strip may have multiple test strips and thus be able to detect multiple analytes. One or more incubation periods may be unnecessary in some implementations; in other implementations, one or more incubation periods may be longer or shorter than specified. Agitation may be required in some implementations but not in other implementations. Analytes other than those associated with Group A Streptococcus may be detected. For example, some in vitro diagnostic devices may be employed to detect urinary tract infections, yeast infections, sexually transmitted diseases, other infectious diseases, etc.
In general, many modifications may be made to adapt a particular situation or material to the teachings provided herein without departing from the essential scope thereof. Therefore, it is intended that the scope not be limited to the particular aspects or embodiments disclosed but include all aspects falling within the scope of the appended claims.
This application claims priority to U.S. Provisional Application Ser. No. 63/051,626, titled “IN VITRO DIAGNOSTIC DEVICE,” filed on Jul. 14, 2020; U.S. Provisional Application Ser. No. 63/049,452, titled “IN VITRO DIAGNOSTIC DEVICE,” filed on Jul. 8, 2020; and U.S. Provisional Application Ser. No. 63/037,595, titled “IN VITRO DIAGNOSTIC DEVICE,” filed on Jun. 10, 2020. This application incorporates the entire contents of the foregoing applications herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3963355 | Aldridge et al. | Jun 1976 | A |
| 4673639 | Slifkin | Jun 1987 | A |
| 4808524 | Snyder et al. | Feb 1989 | A |
| 4920046 | McFarland et al. | Apr 1990 | A |
| 4943522 | Eisinger et al. | Jul 1990 | A |
| 5141850 | Cole et al. | Aug 1992 | A |
| 5356782 | Moorman et al. | Oct 1994 | A |
| 5415994 | Imrich et al. | May 1995 | A |
| 5827675 | Skiffington et al. | Oct 1998 | A |
| 5869003 | Nason | Feb 1999 | A |
| 5879635 | Nason | Mar 1999 | A |
| 5965453 | Skiffington et al. | Oct 1999 | A |
| 6030835 | Musser et al. | Feb 2000 | A |
| 6180395 | Skiffington et al. | Jan 2001 | B1 |
| 6248294 | Nason | Jun 2001 | B1 |
| 6284459 | Nova | Sep 2001 | B1 |
| 6399295 | Kaylor et al. | Jun 2002 | B1 |
| 6524530 | Igarashi et al. | Feb 2003 | B1 |
| 6573040 | Everhart et al. | Jun 2003 | B2 |
| 6686170 | Flanders et al. | Feb 2004 | B1 |
| 6824975 | Hubscher et al. | Nov 2004 | B2 |
| 6890484 | Bautista et al. | May 2005 | B2 |
| 6991898 | O'Connor | Jan 2006 | B2 |
| 7078061 | Debad et al. | Jul 2006 | B2 |
| 7090803 | Gould et al. | Aug 2006 | B1 |
| 7098040 | Kaylor et al. | Aug 2006 | B2 |
| 7189522 | Esfandiari | Mar 2007 | B2 |
| 7312071 | Lu | Dec 2007 | B2 |
| 7371582 | Nahm et al. | May 2008 | B2 |
| 7416892 | Battrell et al. | Aug 2008 | B2 |
| 7444005 | Bachur et al. | Oct 2008 | B2 |
| 7666614 | Cheng et al. | Feb 2010 | B2 |
| 7682801 | Esfandiari | Mar 2010 | B2 |
| 7780914 | Chandler et al. | Aug 2010 | B2 |
| 7863053 | Lyng et al. | Jan 2011 | B2 |
| 7932099 | Egan et al. | Apr 2011 | B2 |
| 8038965 | Keren | Oct 2011 | B2 |
| 8067246 | Marlborough et al. | Nov 2011 | B2 |
| 8211715 | Royds | Jul 2012 | B1 |
| 8216832 | Battrell et al. | Jul 2012 | B2 |
| 8380541 | Holmes | Feb 2013 | B1 |
| 8389230 | Ohshiro | Mar 2013 | B2 |
| 8399261 | Kabir et al. | Mar 2013 | B2 |
| 8507259 | Esfandiari | Aug 2013 | B2 |
| 8664001 | Niskanen et al. | Mar 2014 | B2 |
| 8845978 | Johnson | Sep 2014 | B2 |
| 8877450 | Esfandiari | Nov 2014 | B2 |
| 9027420 | Ward | May 2015 | B1 |
| 9052314 | Dinello et al. | Jun 2015 | B2 |
| 9115382 | Bell et al. | Aug 2015 | B2 |
| 9327284 | Rosman et al. | May 2016 | B2 |
| 9435805 | Sanders et al. | Sep 2016 | B2 |
| 9453996 | Delahunt et al. | Sep 2016 | B2 |
| 9777310 | Nibhanipudi | Oct 2017 | B2 |
| 9784734 | Esfandiari | Oct 2017 | B2 |
| 9791437 | Egan et al. | Oct 2017 | B2 |
| 9857372 | Pulitzer et al. | Jan 2018 | B1 |
| 9857373 | Pulitzer et al. | Jan 2018 | B1 |
| 9903863 | Ohmiya | Feb 2018 | B2 |
| 9932629 | Hopper | Apr 2018 | B2 |
| 10119968 | Lansing et al. | Nov 2018 | B2 |
| 10331924 | Pulitzer et al. | Jun 2019 | B2 |
| 10473659 | Pulitzer et al. | Nov 2019 | B2 |
| 10527555 | Pulitzer et al. | Jan 2020 | B2 |
| 20020085958 | Nemcek et al. | Jul 2002 | A1 |
| 20020148729 | Armstrong | Oct 2002 | A1 |
| 20030027359 | Hudak | Feb 2003 | A1 |
| 20030119202 | Kaylor et al. | Jun 2003 | A1 |
| 20030211634 | Jerome et al. | Nov 2003 | A1 |
| 20040078219 | Kaylor et al. | Apr 2004 | A1 |
| 20040100376 | Lye et al. | May 2004 | A1 |
| 20040151632 | Badley et al. | Aug 2004 | A1 |
| 20050101841 | Kaylor et al. | May 2005 | A9 |
| 20050131314 | Hird et al. | Jun 2005 | A1 |
| 20050249633 | Blatt et al. | Nov 2005 | A1 |
| 20050250141 | Lambert et al. | Nov 2005 | A1 |
| 20060014227 | Fleming et al. | Jan 2006 | A1 |
| 20060094028 | Dominick et al. | May 2006 | A1 |
| 20060166374 | Hubscher et al. | Jul 2006 | A1 |
| 20060292700 | Wang et al. | Dec 2006 | A1 |
| 20070003115 | Patton et al. | Jan 2007 | A1 |
| 20070092402 | Wu et al. | Apr 2007 | A1 |
| 20070143035 | Petruno | Jun 2007 | A1 |
| 20070287198 | Laborde et al. | Dec 2007 | A1 |
| 20080081341 | Maher et al. | Apr 2008 | A1 |
| 20080112847 | Chen | May 2008 | A1 |
| 20080166701 | Ohmiya et al. | Jul 2008 | A1 |
| 20080194013 | Shida et al. | Aug 2008 | A1 |
| 20080206849 | Zak et al. | Aug 2008 | A1 |
| 20080260581 | Rosman et al. | Oct 2008 | A1 |
| 20080286831 | Liang | Nov 2008 | A1 |
| 20090024058 | Blowick et al. | Jan 2009 | A1 |
| 20090047691 | Huwig et al. | Feb 2009 | A1 |
| 20090061507 | Ho | Mar 2009 | A1 |
| 20090104690 | Bayliff et al. | Apr 2009 | A1 |
| 20090246751 | Jensen et al. | Oct 2009 | A1 |
| 20090263854 | Jacono et al. | Oct 2009 | A1 |
| 20090304778 | Sanders et al. | Dec 2009 | A1 |
| 20090305231 | Weidemaier et al. | Dec 2009 | A1 |
| 20100035239 | Sampath et al. | Feb 2010 | A1 |
| 20100273177 | Piasio et al. | Oct 2010 | A1 |
| 20100279308 | Morrow et al. | Nov 2010 | A1 |
| 20100323343 | Egan et al. | Dec 2010 | A1 |
| 20110008909 | Homrig et al. | Jan 2011 | A1 |
| 20110045515 | Bell et al. | Feb 2011 | A1 |
| 20110053181 | Hazama et al. | Mar 2011 | A1 |
| 20110144535 | Guirguis | Jun 2011 | A1 |
| 20110212002 | Curry | Sep 2011 | A1 |
| 20110213619 | Henke | Sep 2011 | A1 |
| 20110256541 | Ecker | Oct 2011 | A1 |
| 20120002199 | Ben-David et al. | Jan 2012 | A1 |
| 20120075626 | Geva et al. | Mar 2012 | A1 |
| 20120076693 | Hopper | Mar 2012 | A1 |
| 20120082977 | Rajagopal et al. | Apr 2012 | A1 |
| 20120284046 | Baym et al. | Nov 2012 | A1 |
| 20130023444 | Kovalenko | Jan 2013 | A1 |
| 20130034869 | Whitesides et al. | Feb 2013 | A1 |
| 20130130404 | Mehra et al. | May 2013 | A1 |
| 20130149776 | Sharrock et al. | Jun 2013 | A1 |
| 20130170724 | Clemens | Jul 2013 | A1 |
| 20130196337 | Ren et al. | Aug 2013 | A1 |
| 20130230844 | Egan et al. | Sep 2013 | A1 |
| 20140011190 | Parviainen et al. | Jan 2014 | A1 |
| 20140072960 | Lansing | Mar 2014 | A1 |
| 20140093969 | Johnson | Apr 2014 | A1 |
| 20140134073 | Fuller | May 2014 | A1 |
| 20140227796 | Gold | Aug 2014 | A1 |
| 20140271410 | Bosma | Sep 2014 | A1 |
| 20140286550 | Beule et al. | Sep 2014 | A1 |
| 20140315221 | Morsey | Oct 2014 | A1 |
| 20150024415 | Lu et al. | Jan 2015 | A1 |
| 20150031014 | Lu et al. | Jan 2015 | A1 |
| 20150044098 | Smart et al. | Feb 2015 | A1 |
| 20150112248 | Helliwell et al. | Apr 2015 | A1 |
| 20150211966 | Hsu et al. | Jul 2015 | A1 |
| 20150241455 | Parsons et al. | Aug 2015 | A1 |
| 20160051235 | Wan | Feb 2016 | A1 |
| 20160139156 | Lakdawala | May 2016 | A1 |
| 20160243543 | Lui et al. | Aug 2016 | A1 |
| 20160266118 | Cho et al. | Sep 2016 | A1 |
| 20160292393 | Balwani | Oct 2016 | A1 |
| 20160304827 | Parikh | Oct 2016 | A1 |
| 20160313307 | Titmus et al. | Oct 2016 | A1 |
| 20160313308 | Titmus et al. | Oct 2016 | A1 |
| 20160313319 | Titmus et al. | Oct 2016 | A1 |
| 20160327506 | English et al. | Nov 2016 | A1 |
| 20170113221 | Hoffman et al. | Apr 2017 | A1 |
| 20170173585 | Mahony et al. | Jun 2017 | A1 |
| 20170183714 | Shen et al. | Jun 2017 | A1 |
| 20170191996 | Johnson et al. | Jul 2017 | A1 |
| 20170196962 | Nizet et al. | Jul 2017 | A1 |
| 20170219573 | Needham et al. | Aug 2017 | A1 |
| 20170226593 | Astatke et al. | Aug 2017 | A1 |
| 20170234817 | Bischof et al. | Aug 2017 | A1 |
| 20170266657 | Ayub et al. | Sep 2017 | A1 |
| 20170322203 | Ghatak | Nov 2017 | A1 |
| 20170335379 | Armes | Nov 2017 | A1 |
| 20180020823 | Holmes et al. | Jan 2018 | A1 |
| 20180021771 | Tamir | Jan 2018 | A1 |
| 20180209970 | Kato et al. | Jul 2018 | A1 |
| 20180229232 | Chang et al. | Aug 2018 | A1 |
| 20180311664 | Lansing et al. | Nov 2018 | A1 |
| 20190232282 | Pierson et al. | Aug 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1024354 | Aug 2000 | EP |
| 0861330 | Aug 2003 | EP |
| 1338338 | Aug 2003 | EP |
| 1697717 | Sep 2006 | EP |
| 0981729 | Apr 2007 | EP |
| 2879581 | Jun 2015 | EP |
| 1714133 | Jul 2017 | EP |
| WO2010129726 | Nov 2010 | WO |
| Entry |
|---|
| Clare, “I'm skeptical about . . . Strep throat,” Roberty Alan Clare, MD, Sep. 8, 2015, retrieved from https://robertclaremd.com/im-skeptical-about-strep-throat/, last visited Feb. 16, 2021, 8 pages. |
| CMS, “Explanation of CLIA waivers, CMS fact sheet,” last visited Oct. 11, 2018, 3 pages. |
| FDA,“Overview of IVD Regulation,” retrieved from https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation, last visited Feb. 16, 2021, 6 pages. |
| FDA, “Overview of Device Regulation,” retrieved from https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation, last visited Feb. 17, 2021, 3 pages. |
| Finkelstein et al., “Rapid Streptococcal Antigen Detection Test Performed by Parents of Children with Sore Throat,” Society of Participatory Medicine, Mar. 25, 2017, retrieved from https://participatorymedicine.org/journal/evidence/research/2017/03/25/rapid-streptococcal-antigen-detection-test-performed-by-parents-of-children-with-sore-hroat/#:˜:text=Rapid%20Streptococcal%20Antigen%20Detection%20Test%20Performed%20by%20Parents,and%20Warner%20V.%20Slack%20|%20March%2025,%202017, 4 pages. |
| Quidel Corporation,“ Sofia Strep A FIA,” retrieved from https://www.quidel.com/sites/default/files/product/documents/EF1243801EN01.pdf, 8 pages. |
| Quidel Corporation, “Sofia Strep A+ FIA,” retrieved from https://www.quidel.com/sites/default/files/product/documents/CL2025300EN00.pdf, 15 pages. |
| Trafton, “Home strep test could savef time and money,” MIT News Office, May 10, 2017, retrieved from https://news.mit.edu/2017/home-strep-test-could-save-time-money-0511, last visited Feb. 16, 2021, 4 pages. |
| Wikipedia,“Lateral flow test,” retrieved from https://en.wikipedia.org/wiki/Lateral_flow_test, last visited Oct. 11, 2018, 3 pages. |
| Wikipedia,“Streptococcus,” retrieved from https://en.wikipedia.org/wiki/Streptococcus, last visited Oct. 11, 2018, 6 pages. |
| Wondview, Wondview Throat Testing Kit-25 Tests Per Kit-EXP-Aug. 15, 2021, Amazon, retrieved from https://www.amazon.com/Wondview-Throat-Testing-Kit/dp/B08LHLPVRY, last visited Feb. 16, 2021, 4 pages. |
| Thomas, Shane, Written Opinion of the International Search Authority, Form PCT/ISA/237, dated Sep. 16, 2021, 6 pages, United States. |
| Thomas, Shane, International Search Report, Form PCT/ISA/210, dated Sep. 16, 2021, 2 pages, United States. |
| Number | Date | Country | |
|---|---|---|---|
| 20210387188 A1 | Dec 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63051626 | Jul 2020 | US | |
| 63049452 | Jul 2020 | US | |
| 63037595 | Jun 2020 | US |